Table 2.
Treatment Outcomes of Long-Term TDF Therapy in the Treatment-Naïve and Treatment-Experienced CHB Groups
| Characteristics | 1 Year (n=426) | 2 Years (n=347) | 3 Years (n=236) | |
|---|---|---|---|---|
| Virologic response | Total | 319/426 (74.9) | 301/347 (86.7) | 211/236 (89.4) |
| Naïve | 133/184 (72.3) | 119/134 (88.8) | 66/78 (84.6) | |
| Experienced | 186/242 (76.9) | 182/213 (85.4) | 145/158 (91.8) | |
| p-value | 0.334 | 0.462 | 0.145 | |
| HBeAg seroconversion/loss | Total | 26/273 (9.5) | 31/227 (13.7) | 22/151 (13.9) |
| Naïve | 17/99 (17.2) | 20/74 (27.0) | 9/40 (22.5) | |
| Experienced | 9/174 (5.2) | 11/153 (7.2) | 13/109 (11.9) | |
| p-value | 0.002 | <0.001 | 0.176 | |
| ALT normalization | Total | 345/424 (81.4) | 291/343 (84.8) | 196/230 (85.2) |
| Naïve | 152/182 (83.5) | 121/133 (91.0) | 64/77 (83.1) | |
| Experienced | 193/242 (79.8) | 170/210 (81.0) | 132/153 (86.3) | |
| p-value | 0.324 | 0.018 | 0.660 | |
| Virologic breakthrough | Total | 3/426 (0.7) | 4/347 (1.2) | 3/236 (1.3) |
| Naïve | 0/184 (0.0) | 1/134 (0.7) | 3/78 (3.8) | |
| Experienced | 3/242 (1.2) | 3/213 (1.4) | 0/158 (0.0) | |
| p-value | 0.352 | 0.963 | 0.062 | |
| Genotypic resistance | Total | 0 | 0 | 0 |
| Naïve | 0 | 0 | 0 | |
| Experienced | 0 | 0 | 0 | |
| p-value | - | - | - | |
Data are presented as number/number (%).
TDF, tenofovir disoproxil fumarate; CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase.